Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Jan 10;28(2):202-6.
doi: 10.1200/JCO.2009.25.0753. Epub 2009 Nov 23.

Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904

Jeffrey A Bogart  1 , Lydia Hodgson, Stephen L Seagren, A William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T Turrisi 3rd, John Reilly, Ajeet Gajra, Everett E Vokes, Mark R Green
Affiliations
Clinical Trial

Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904

Jeffrey A Bogart et al. J Clin Oncol. .

Abstract

Purpose: The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) has not been defined.

Patients and methods: Cancer and Leukemia Group B trial 39904 prospectively assessed accelerated, once-daily, three-dimensional radiotherapy for early-stage NSCLC. The primary objectives were to define the maximally accelerated course of conformal radiotherapy and to describe the short-term and long-term toxicity of therapy. Entry was limited to patients with clinical stage T1N0 or T2N0 NSCLC (< 4 cm) and pulmonary dysfunction. The nominal total radiotherapy dose remained at 70 Gy, while the number of daily fractions in each successive cohort was reduced.

Results: Thirty-nine eligible patients were accrued (eight patients each on cohorts 1 to 4 and seven patients on cohort 5) between January 2001 and July 2005. One grade 3 nonhematologic toxicity was observed in both cohort 3 (dyspnea) and cohort 4 (pain). The major response rate was 77%. After a median follow-up time of 53 months, the actuarial median survival time of all eligible patients was 38.5 months. Local relapse was observed in three patients.

Conclusion: Accelerated conformal radiotherapy was well tolerated in a high-risk population with clinical stage I NSCLC. Outcomes are comparable to prospective reports of alternative therapies, including stereotactic body radiation therapy and limited resection, with less apparent severe toxicity. Further investigation of this approach is warranted.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Overall survival for all patients on Cancer and Leukemia Group B trial 39904.
See this image and copyright information in PMC

References

    1. Mountain CF. A new international staging system for lung cancer. Chest. 1986;89(suppl 4):225S–233S. - PubMed
    1. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198–1205. - PubMed
    1. Kyasa MJ, Jazieh AR. Characteristics and outcomes of patients with unresected early-stage non-small cell lung cancer. South Med J. 2002;95:1149–1152. - PubMed
    1. McGarry RC, Song G, des Rosiers P, et al. Observation-only management of early stage, medically inoperable lung cancer: Poor outcome. Chest. 2002;121:1155–1158. - PubMed
    1. Timmerman RD, Paulus R, Galvin J, et al. Toxicity analysis of RTOG 0236 using stereotactic body radiation therapy to treat medically inoperable early stage lung cancer patients. Int J Radiat Oncol Biol Phys. 2007;69(suppl 3):S86.

Publication types